(Q39814919)

14 September 2017

title

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma (English)

1 reference

14 September 2017

Fumitaka Kikkawa

1 reference

14 September 2017

Tomoko Inaba

1 reference

14 September 2017

Kazuhiko Ino

1 reference

14 September 2017

Hiroaki Kajiyama

1 reference

14 September 2017

Eiko Yamamoto

1 reference

14 September 2017

Kiyosumi Shibata

1 reference

14 September 2017

Akihiro Nawa

1 reference

14 September 2017

Tetsuro Nagasaka

1 reference

14 September 2017

Hidetoshi Akimoto

1 reference

14 September 2017

Osamu Takikawa

1 reference

14 September 2017

language of work or name

English

0 references

publication date

8 August 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

115

1 reference

14 September 2017

1 reference

14 September 2017

page(s)

185-192

1 reference

Primary ovarian cancer chemotherapy: current standards of care

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Systemic therapy for ovarian cancer: current status and new treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

Recent advances and current challenges in tumor immunology and immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.07.015

10.1016/J.YGYNO.2009.07.015

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference